Sichuan Kelun-Biotech Biopharmaceutical: Lowered Expectations Post Results
Losses are expected to increase by 32% to CN¥3.15 per share for Sichuan Kelun-Biotech Biopharmaceutical. This is a significant change ...
- Latest
- Trending
Losses are expected to increase by 32% to CN¥3.15 per share for Sichuan Kelun-Biotech Biopharmaceutical. This is a significant change ...
NextCure, Inc. (NXTC) is a biopharmaceutical company focused on novel immunomedicines. Strong financials, positive outlook, and promising pipeline.
Experience Ligand Pharmaceuticals Incorporated's financial report and stock price prediction in the healthcare sector. Discover their strategic growth trajectory.
Indivior reported a fourth-quarter pretax profit of $61 million, compared to a loss of $256 million in the previous year. ...
Investigation reveals significant delays in processing complaints against UK drug companies, raising concerns about patient safety and public health. Increased ...
The weight-loss drugs of Eli Lilly and Novo Nordisk have led to soaring share prices as investors anticipate high demand ...
RBC Capital Markets initiates coverage on Biohaven Pharmaceutical, assigning an outperform rating with a $62 price target. The firm praises ...
A new wave of companies is racing to achieve trillion-dollar valuations, joining household names like Apple and Microsoft. Berkshire Hathaway, ...
Lexaria Bioscience announces a $3.6 million offering and private placement to enhance operational capabilities and drive innovation in the pharmaceutical ...
Wolfe Research initiates coverage on Roivant Sciences, assigning an outperform rating with a price target of $17.00. Their analysis highlights ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.